A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 July 2016
|
| In: |
BMC cancer
Year: 2016, Jahrgang: 16 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-016-2449-0 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1186/s12885-016-2449-0 Verlag, Volltext: https://doi.org/10.1186/s12885-016-2449-0 
|
| Verfasserangaben: | N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1586218441 | ||
| 003 | DE-627 | ||
| 005 | 20220815090609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190115s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-016-2449-0 |2 doi | |
| 035 | |a (DE-627)1586218441 | ||
| 035 | |a (DE-576)516218441 | ||
| 035 | |a (DE-599)BSZ516218441 | ||
| 035 | |a (OCoLC)1341033491 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hänse, Nicole |d 1990- |e VerfasserIn |0 (DE-588)1112570209 |0 (DE-627)866553517 |0 (DE-576)47663685X |4 aut | |
| 245 | 1 | 2 | |a A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors |c N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran |
| 264 | 1 | |c 07 July 2016 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.01.2019 | ||
| 520 | |a Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells. | ||
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Haag, Georg Martin |d 1979- |e VerfasserIn |0 (DE-588)133390934 |0 (DE-627)544043863 |0 (DE-576)29981548X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 16(2016) Artikel-Nummer 420, 10 Seiten |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors |
| 773 | 1 | 8 | |g volume:16 |g year:2016 |g extent:10 |a A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-016-2449-0 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12885-016-2449-0 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190115 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 133390934 |a Haag, Georg Martin |m 133390934:Haag, Georg Martin |d 910000 |e 910000PH133390934 |k 0/910000/ |p 6 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |e 910000PM132561972 |k 0/910000/ |p 5 | ||
| 999 | |a KXP-PPN1586218441 |e 3045297986 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Nicole","family":"Hänse","display":"Hänse, Nicole"},{"display":"Marmé, Frederik","family":"Marmé","role":"aut","given":"Frederik"},{"role":"aut","given":"Georg Martin","family":"Haag","display":"Haag, Georg Martin"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors","title_sort":"phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors"}],"note":["Gesehen am 15.01.2019"],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"07 July 2016"}],"id":{"eki":["1586218441"],"doi":["10.1186/s12885-016-2449-0"]},"physDesc":[{"extent":"10 S."}],"name":{"displayForm":["N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran"]},"recId":"1586218441","relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumorsBMC cancer","pubHistory":["1.2001 -"],"origin":[{"dateIssuedDisp":"2001-","dateIssuedKey":"2001","publisher":"BioMed Central ; Springer","publisherPlace":"London ; Berlin ; Heidelberg"}],"note":["Gesehen am 22.05.20"],"title":[{"title":"BMC cancer","title_sort":"BMC cancer"}],"id":{"eki":["326643710"],"issn":["1471-2407"],"zdb":["2041352-X"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"326643710","part":{"volume":"16","extent":"10","text":"16(2016) Artikel-Nummer 420, 10 Seiten","year":"2016"},"language":["eng"]}]} | ||
| SRT | |a HAENSENICOPHASEITRIA0720 | ||